Literature DB >> 6433689

Left ventricular mechanics in dilated cardiomyopathy.

W K Laskey, M S Sutton, G Zeevi, J W Hirshfeld, N Reichek.   

Abstract

The influence of altered chamber shape on the evaluation of left ventricular (LV) mechanics in idiopathic dilated cardiomyopathy (IDC) is unknown. Nine patients with IDC and 7 subjects with normal LV function were studied with simultaneous LV pressure and M-mode echographic recordings in order to derive LV meridional wall stress. The major axis of the left ventricle, determined from the left ventriculogram at rest, allowed for derivation of circumferential wall stress. The IDC group was characterized by larger end-diastolic and end-systolic LV volumes, increased LV mass, depressed angiographic ejection fraction and more spherical LV chamber shape. Both end-systolic meridional (114 +/- 30 kdyne/cm2) and circumferential (251 +/- 73 kdyne/cm2) wall stresses were elevated in patients with IDC, although the ratio of these stresses was less than normal (2.2 +/- 0.1 vs 2.7 +/- 0.2, respectively). LV load alteration with phenylephrine or nitroglycerin allowed for construction of end-systolic stress-minor-axis dimension and end-systolic stress-minor-axis shortening relations. Similar mean slopes of the meridional end-systolic stress-dimension relation were noted in IDC and normal subjects, although the line was displaced to the right in IDC. The slope of the circumferential end-systolic stress-dimension relation was, however, decreased in patients with IDC. Moreover, the end-systolic stress-fractional minor-axis shortening relation in patients with IDC was displaced downward from the normal relation supporting depressed contractile function in these IDC patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6433689     DOI: 10.1016/0002-9149(84)90261-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Does left ventricular shape influence clinical outcome in heart failure?

Authors:  K J Harjai; R Edupuganti; E Nunez; T Turgut; L Scott; N G Pandian
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

2.  Elongation as a new shape index for the left ventricle.

Authors:  B Knap; G Juznic; A F Bren; G Drzewiecki; A Noordergraaf
Journal:  Int J Cardiovasc Imaging       Date:  2002-12       Impact factor: 2.357

Review 3.  Global left ventricular remodeling with the Acorn Cardiac Support Device: hemodynamic and angiographic findings in dogs with heart failure.

Authors:  Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

4.  The use of levodopa, an oral dopamine precursor, in congestive heart failure.

Authors:  G Broderick; S I Rajfer
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

5.  Left-ventricular cavity dimensions in children with normal and dilated hearts.

Authors:  D M Regen; T P Graham; R K Wyse; J Deanfield; R C Franklin
Journal:  Pediatr Cardiol       Date:  1988       Impact factor: 1.655

6.  Dyspnoea of cardiac origin in 67 year old men: (1). Relation to systolic left ventricular function and wall stress. The study of men born in 1913.

Authors:  K Caidahl; H Eriksson; M Hartford; J Wikstrand; I Wallentin; K Svärdsudd
Journal:  Br Heart J       Date:  1988-03

7.  Estimation of left-ventricular systolic performance and its determinants in man from pressures and dimensions of one beat: effects of aortic valve stenosis and replacement.

Authors:  D M Regen; H Nonogi; O M Hess
Journal:  Heart Vessels       Date:  1990       Impact factor: 2.037

8.  Non-invasive Model-Based Assessment of Passive Left-Ventricular Myocardial Stiffness in Healthy Subjects and in Patients with Non-ischemic Dilated Cardiomyopathy.

Authors:  Myrianthi Hadjicharalambous; Liya Asner; Radomir Chabiniok; Eva Sammut; James Wong; Devis Peressutti; Eric Kerfoot; Andrew King; Jack Lee; Reza Razavi; Nicolas Smith; Gerald Carr-White; David Nordsletten
Journal:  Ann Biomed Eng       Date:  2016-09-07       Impact factor: 3.934

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.